secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-09-18T20:27:15+00:00
Accession:  0001213900-26-101434
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial shareholders approve 5x authorized-share increase to 500M and new 2026 equity plans
--------------------------------------------------------------------------------

- Authorized common shares increased from 100M to 500M (1,239,968 votes for, 37,210 against).
- 2026 Equity Incentive Plan approved: 3,078,147 new shares plus 196,670 returning shares and 5% annual evergreen through Jan 1, 2036.
- Series F warrant exercise issuance of up to 552,940 shares approved under Nasdaq Listing Rule 5635(d).
- 2017 Plan share pool raised from 200,000 to 225,666 shares; ESPP approved; CBIZ CPAs ratified as auditor.
- Meeting partially adjourned on 4 proposals pending Nasdaq conditional approval; reconvenes Oct 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026101434/0001213900-26-101434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026101434/ea0305933-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-101434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer